Merck & Co. Inc. (MRK)

86.14
1.10 1.30
NYSE : Health Technology
Prev Close 85.06
Open 85.59
Day Low/High 85.45 / 86.12
52 Wk Low/High 66.10 / 87.07
Volume 767.33K
Avg Volume 9.94M
Exchange NYSE
Shares Outstanding 2.56B
Market Cap 213.69B
EPS 2.30
P/E Ratio 39.37
Div & Yield 2.20 (2.55%)

Latest News

Merck Announces Leadership Changes To Investor Relations Team

Merck Announces Leadership Changes To Investor Relations Team

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Peter Dannenbaum has been promoted to vice president, Investor Relations, effective Aug.

Bullpen Update

These companies already posted strong earnings this season and are not economically sensitive.

LYNPARZA® (olaparib) Phase 3 PROfound Trial In HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

LYNPARZA® (olaparib) Phase 3 PROfound Trial In HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 PROfound trial of LYNPARZA in men with metastatic castration-resistant prostate cancer (mCRPC) who have an homologous...

Trump Just Deepened the Tariff War -- Retail Investors Were the Smart Ones

Trump Just Deepened the Tariff War -- Retail Investors Were the Smart Ones

Retail investors are sitting pretty after Trump enacted more tariffs. See their fancy footwork executed in July.

FDA Approves New Monotherapy Indication For Merck's KEYTRUDA® (pembrolizumab)

FDA Approves New Monotherapy Indication For Merck's KEYTRUDA® (pembrolizumab)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks decline Tuesday as investors digest a plate full of earnings reports, the start of the two-day Fed meeting, and President Trump's remarks doubting the success of U.S. trade talks with China.

Merck Beats Q2 Earnings Forecast and Boosts Outlook as Keytruda Sales Impress

Merck Beats Q2 Earnings Forecast and Boosts Outlook as Keytruda Sales Impress

Merck posted stronger-than-expected second quarter earnings Tuesday, and raised its full-year profit guidance, as its blockbuster breast cancer treatment Keytruda saw sales rise past $2.6 billion.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

Financial Highlights Package

Financial Highlights Package

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2019.

Capital One, Apple, AMD, Beyond Meat, Federal Reserve - 5 Things You Must Know

Capital One, Apple, AMD, Beyond Meat, Federal Reserve - 5 Things You Must Know

U.S. stock futures point lower on Tuesday, the first day of a critical two-day meeting of the Federal Reserve, and ahead of quarterly earnings from tech giant Apple; the earnings calendar also includes reports from Merck, Procter & Gamble, Mastercard and AMD; Capital One says a hacker got access to the personal information of more than 100 million of its credit card customers and applicants.

Merck Receives Positive EU CHMP Opinion For ZERBAXA® 3g Dose (ceftolozane And Tazobactam) For The Treatment Of Adults With Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)

Merck Receives Positive EU CHMP Opinion For ZERBAXA® 3g Dose (ceftolozane And Tazobactam) For The Treatment Of Adults With Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending ZERBAXA® 3g dose...

Two Pharmaceutical Stocks That Jim Cramer's Watching

Two Pharmaceutical Stocks That Jim Cramer's Watching

Jim Cramer's eyeing Merck and Pfizer. Here's why.

Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy Met Primary Endpoint Of Pathological Complete Response (pCR) In Pivotal Phase 3 KEYNOTE-522 Trial In Patients With Triple-Negative Breast Cancer (TNBC)

Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy Met Primary Endpoint Of Pathological Complete Response (pCR) In Pivotal Phase 3 KEYNOTE-522 Trial In Patients With Triple-Negative Breast Cancer (TNBC)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-522 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy met one of the dual-primary endpoints of...

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) In Combination With Inlyta® (axitinib) As First-Line Treatment For Advanced Renal Cell Carcinoma

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) In Combination With Inlyta® (axitinib) As First-Line Treatment For Advanced Renal Cell Carcinoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA,...

Merck Announces Presentation Of Phase 2b Results For Investigational HIV-1 Therapy Islatravir (MK-8591) At IAS 2019

Merck Announces Presentation Of Phase 2b Results For Investigational HIV-1 Therapy Islatravir (MK-8591) At IAS 2019

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the results from a Phase 2b clinical trial evaluating the efficacy, tolerability, and safety of islatravir (MK-8591), the company's investigational nucleoside reverse...

Jim Cramer: It's Looking Like the 1980s

Jim Cramer: It's Looking Like the 1980s

Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.

Merck Announces Fourth-Quarter 2019 Dividend

Merck Announces Fourth-Quarter 2019 Dividend

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

Merck Presents Early Evidence On Extended Delivery Of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) Via Subdermal Implant

Merck Presents Early Evidence On Extended Delivery Of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) Via Subdermal Implant

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today results from a Phase 1 study evaluating the pharmacokinetics and safety of a prototype subdermal drug-eluting implant for extended administration of islatravir, the...

Merck And Eisai Receive Third Breakthrough Therapy Designation From FDA For KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment

Merck And Eisai Receive Third Breakthrough Therapy Designation From FDA For KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.

Sure Petcare Launches SureFeed® Microchip Pet Feeder Connect

Sure Petcare Launches SureFeed® Microchip Pet Feeder Connect

Sure Petcare, the pet technology specialist, today announced the launch of the SureFeed® Microchip Pet Feeder Connect, the next generation of the best-selling SureFeed Microchip Pet Feeder, which monitors the eating behavior of pets.

Jim Cramer: Don't Play Earnings Season, Invest in It

Jim Cramer: Don't Play Earnings Season, Invest in It

Here are my five rules for handling earnings season.

I'm Looking at Gilead and Merck for Buy Entry Positions

I'm Looking at Gilead and Merck for Buy Entry Positions

Let's see if either of these names provide an entry this week.

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

Here's what you need to know if AstraZeneca's pipeline could affect your portfolio.

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

The Dow & S&P 500 closed at record highs with the S&P barely missing ending the day above 3,000.

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?

Merck Highlights Commitment To HIV Research With Presentations For Investigational Anti-HIV Agent MK-8591 At IAS 2019

Merck Highlights Commitment To HIV Research With Presentations For Investigational Anti-HIV Agent MK-8591 At IAS 2019

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the results from studies evaluating MK-8591, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), are scheduled to be presented at...

FDA Accepts Merck's Supplemental Biologics License Applications For KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule For Melanoma And Multiple Other Indications

FDA Accepts Merck's Supplemental Biologics License Applications For KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule For Melanoma And Multiple Other Indications

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

TheStreet Quant Rating: A+ (Buy)